All news

What Regeneron Pharmaceuticals (REGN)'s Liver Drug Trial Results Mean For Shareholders

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Regeneron Pharmaceuticals (REGN) reported promising early-stage human trial data for its CIDEBsiRNA drug, showing significant dose-dependent liver fat reductions and sustained improvements in liver injury markers for MASLD. These results reinforce Regeneron's strategy of investing heavily in long-cycle, genetics-based programs while maintaining strong earnings from existing products.

Read original source

REGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.